GW-1100 is primarily utilized in research settings as a selective antagonist for the GPR40 receptor, which is involved in the regulation of insulin secretion. It is often used in studies to investigate the role of GPR40 in metabolic processes, particularly in the context of diabetes and glucose homeostasis. By blocking GPR40, researchers can better understand its function and explore potential therapeutic targets for metabolic disorders. Additionally, GW-1100 is employed in pharmacological experiments to study the effects of GPR40 inhibition on pancreatic beta cells and insulin release, contributing to the development of novel treatments for type 2 diabetes.